Clarke Neumann - 15 May 2022 Form 4 Insider Report for BIORA THERAPEUTICS, INC. (BIORQ)

Role
Senior Vice President, General Counsel and Secretary
Signature
/s/ Will Pridgen, Attorney-in-Fact for Clarke Neumann
Issuer symbol
BIORQ
Transactions as of
15 May 2022
Net transactions value
-$6,229
Form type
4
Filing time
17 May 2022, 17:27:09 UTC
Previous filing
19 Apr 2022
Next filing
16 Aug 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BIOR Common Stock Tax liability $6,229 -8,305 -2.6% $0.7500 308,320 15 May 2022 Direct F1
transaction BIOR Common Stock Award $0 +239,962 +78% $0.000000 548,282 15 May 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BIOR Stock Option (Right to Buy) Award $0 +387,752 $0.000000 387,752 15 May 2022 Common Stock 387,752 $0.7500 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the release of 24,014 vested restricted stock units on May 15, 2022.
F2 Consists of 239,962 restricted stock units, 25% of which will vest on May 15, 2023, with the remaining shares vesting in equal semi-annual installments through May 15, 2026, subject to the Reporting Person's continued service to the Issuer.
F3 This option represents the right to purchase 387,752 shares of the Issuer's common stock, 8,078 of which vested upon grant, with the remaining shares vesting in equal monthly installments through April 15, 2026, subject to the Reporting Person's continued service to the Issuer.

Remarks:

Senior Vice President, General Counsel and Secretary